首页 | 本学科首页   官方微博 | 高级检索  
     


Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Authors:Lluís Puig  Matthias Augustin  Andrew Blauvelt  Alice B. Gottlieb  Ron Vender  Neil J. Korman  Diamant Thaçi  Yang Zhao  Isabelle Gilloteau  Bintu Sherif  Nicole Williams  Adriana Guana  Mark G. Lebwohl
Affiliation:1. Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;2. Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg-Eppendorf, Hamburg, Germany;3. Oregon Medical Research Center, Portland, Oregon;4. New York Medical College at Metropolitan Hospital, New York, New York;5. Dermatrials Research Inc., Hamilton, Ontario, Canada;6. University Hospitals Cleveland Medical Center, Cleveland, Ohio;g. Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany;h. formerly with Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;i. Novartis Pharma AG, Basel, Switzerland;j. RTI Health Solutions, Research Triangle Park, North Carolina;k. Icahn School of Medicine at Mount Sinai, New York, New York
Abstract:
Keywords:cumulative benefit  itching  pain  psoriasis  quality of life  scaling  secukinumab  AUC  area under the curve  CI  confidence interval  DLQI  Dermatology Life Quality Index  HRQoL  health-related quality of life  MCID  minimal clinically important difference  PASI  Psoriasis Area and Severity Index  PRO  patient-reported outcome
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号